A forward-looking analysis of the Inflation Reduction Act’s structural impact on U.S. pharmaceutical economics The Price Is Wrong: What the […]
The IRA Price Reset: What It Actually Does to Pharma Pricing, and What Comes Next Read Post »
Pharmaceutical companies spend decades constructing legal fortresses around their best-selling drugs. They file dozens of secondary patents on minor formulation
When the Patent Wall Crumbles: Secondary Abandonment and the Death of Drug Evergreening Read Post »
Introduction: Licensing as the Lifeblood of Biopharmaceutical Innovation In biopharmaceutical innovation the drug patent licensing agreement stands as the central,
The Strategic Playbook for Identifying and Securing Drug Patent Licensing Opportunities Read Post »
A practitioner’s guide for pharmaceutical analysts, generics strategists, and investors who need to know when a drug is actually off-patent.
Beyond the API: Mapping the Secondary Patent Thicket to Forecast Generic Entry Read Post »
In the multi-trillion-dollar pharmaceutical industry, there’s an attic. It’s filled not with dust and forgotten relics, but with something far
No Patents, No Problem: The Untapped Power of Drug Repurposing Read Post »
Day one of generic competition is the moment most specialty pharmacies dread. The brand rep stops calling. The PBM’s preferred
Double Your Specialty Pharmacy Margins the Day Generics Launch Read Post »
When Pfizer launched atorvastatin (Lipitor) in 1997, it did not simply sell a cholesterol drug. It built, over the next
Defend Your Blockbuster Drug. Here’s the Playbook. Read Post »
Introduction: The Allure of the Biotech Lottery: Beyond the Hype Scan the financial headlines on any given day, and you’re
In the spring of 2014, a small biotech called Idenix Pharmaceuticals held patents covering certain nucleotide analogue structures with antiviral
Get fresh news and insights, drug patent expirations & more…
